“Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)”. 2025. SKIN The Journal of Cutaneous Medicine 9 (6): s664. https://doi.org/10.25251/h3w8px06.